| 18.48 -0.61 (-3.2%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.1 | 1-year : | 26.98 |
| Resists | First : | 19.78 | Second : | 23.1 |
| Pivot price | 18.71  |
|||
| Supports | First : | 15.79 | Second : | 13.32 |
| MAs | MA(5) : | 18.64 |
MA(20) : | 18.04 |
| MA(100) : | 14.96 |
MA(250) : | 14.9 |
|
| MACD | MACD : | 1 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 74.2 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 20.54 | Low : | 8.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NEO ] has closed above bottom band by 40.6%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.99 - 19.1 | 19.1 - 19.2 |
| Low: | 18.09 - 18.21 | 18.21 - 18.31 |
| Close: | 18.31 - 18.5 | 18.5 - 18.67 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Tue, 05 Dec 2023
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for - Benzinga
Mon, 27 Nov 2023
Is NeoGenomics, Inc. (NEO) a Bad Choice in Diagnostics & Research Monday? - InvestorsObserver
Mon, 20 Nov 2023
What's Driving NeoGenomics Inc's Surprising 42% Stock Rally? - GuruFocus.com
Tue, 07 Nov 2023
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript - Yahoo Finance
Mon, 30 Oct 2023
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Fri, 27 Oct 2023
Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 127 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 93.4 (%) |
| Shares Short | 6,280 (K) |
| Shares Short P.Month | 4,900 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | -16.8 % |
| Operating Margin | -14.6 % |
| Return on Assets (ttm) | -4.1 % |
| Return on Equity (ttm) | -9.9 % |
| Qtrly Rev. Growth | 18 % |
| Gross Profit (p.s.) | 1.47 |
| Sales Per Share | 4.5 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -24 |
| PEG Ratio | 1 |
| Price to Book value | 2.48 |
| Price to Sales | 4.09 |
| Price to Cash Flow | -100.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|